Press release
Rett Syndrome Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
Curious about the latest updates in the Rett Syndrome Pipeline? Click here to explore the therapies and trials making headlines @ Rett Syndrome Pipeline Outlook Report [https://www.delveinsight.com/sample-request/rett-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Rett Syndrome Pipeline Report
* On December 12, 2025 - Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the U.S. Food and Drug Administration (FDA) has approved Daybue Stix (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, for the treatment of Rett syndrome in adult and pediatric patients aged two years and older. The newly approved formulation is designed to provide the same established efficacy and safety profile as the Daybue oral solution, while offering greater flexibility in dosing volume and improved taste options, giving both children and adults living with Rett syndrome more choice and convenience in their treatment experience.
* On December 05, 2025- Ionis Pharmaceuticals Inc . announced a phase 1-2 randomized, double-blind, sham-controlled, multiple-ascending dose (MAD) study to evaluate ION440 in pediatric and adult participants with MECP2 Duplication Syndrome (MDS) and will be conducted in two parts. During Part 1 (MAD) (36 weeks), participants will be randomized in a 3:1 ratio to receive ION440 or sham. Individuals who complete Part 1 may enter Part 2, an open label long-term extension study (LTE), where they will receive ION440 for up to approximately 156 weeks. Multiple dose cohorts (Dose A, Dose B, and Dose C) will be evaluated in the study.
* DelveInsight's Rett Syndrome Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Rett Syndrome treatment.
* The leading Rett Syndrome Companies such as Xuanwu Hospital, Beijing, Aegle Therapeutics, ZEO ScientifiX Inc., Direct Biologics LLC, Rion Inc . and others.
* Promising Rett Syndrome Therapies such as Fingolimod (FTY720), Bionetide, TSHA-102, NNZ-2566, NTI164, ANAVEX2-73 and others.
Want to know which companies are leading innovation in Rett Syndrome? Dive into the full pipeline insights @ Rett Syndrome Clinical Trials Assessment [https://www.delveinsight.com/sample-request/rett-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Rett Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Rett Syndrome Pipeline Report also highlights the unmet needs with respect to the Rett Syndrome.
Rett Syndrome Overview
Rett syndrome is a rare, severe neurodevelopmental disorder that primarily affects girls and leads to progressive impairments in motor skills, communication, cognition, and autonomic function. It is most commonly caused by mutations in the MECP2 gene on the X chromosome, a gene essential for normal brain development and synaptic function.
Rett Syndrome Emerging Drugs
Blarcamesine: Anavex Life Sciences Corp
Blarcamesine is a small molecule, orally administered drug that restores cellular homeostasis by targeting SIMGAR1 and muscarinic receptors that is pivotal to restoring cellular homeostasis and promoting neuroplasticity. The drug candidate has received Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA. Currently, the drug is in Phase III stage of its development for the treatment of Rett syndrome.
TSHA-102: Taysha GTx
TSHA-102 is a self-complementary intrathecal delivered AAV9 gene transfer therapy in clinical evaluation. TSHA-102 is constructed from a neuronal specific promoter, MECP2, a gene essential for neuronal and synaptic function in the brain. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) platform designed to regulate cellular MECP2 expression. TSHA-102 has received Orphan Drug and Rare Pediatric Disease designations from the United States (U.S.) Food and Drug Administration (FDA) and has been granted Orphan Drug designation from the European Commission. Currently, the drug is in Phase I/II stage of its development for the treatment of Rett syndrome.
NGN-401: Neurogene
NGN-401 is an investigational AAV9 gene therapy being developed as a one line treatment for Rett syndrome. It is the first clinical candidate to deliver the full-length human MECP2 gene under the control of Neurogene's EXACT technology. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with Rett Syndrome.
The Rett Syndrome Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Rett Syndrome with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rett Syndrome Treatment.
* Rett Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Rett Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rett Syndrome market.
If you're tracking ongoing Rett Syndrome Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Rett Syndrome Treatment Drugs [https://www.delveinsight.com/sample-request/rett-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Rett Syndrome Companies
Xuanwu Hospital, Beijing, Aegle Therapeutics, ZEO ScientifiX Inc., Direct Biologics LLC, Rion Inc . and others.
Rett Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Rett Syndrome Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
From emerging drug candidates to competitive intelligence, the Rett Syndrome Pipeline Report covers it all - check it out now @ Rett Syndrome Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/rett-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Rett Syndrome Pipeline Report
* Coverage- Global
* Rett Syndrome Companies- Xuanwu Hospital, Beijing, Aegle Therapeutics, ZEO ScientifiX Inc., Direct Biologics LLC, Rion Inc . and others.
* Rett Syndrome Therapies- Fingolimod (FTY720), Bionetide, TSHA-102, NNZ-2566, NTI164, ANAVEX2-73 and others.
* Rett Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Rett Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in oncology research - discover what's next for the Rett Syndrome treatment landscape in this detailed analysis @ Rett Syndrome Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/rett-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Rett Syndrome: Overview
* Pipeline Therapeutics
* Therapeutics Assessment
* Rett Syndrome - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Blarcamesine: Anavex Life Sciences Corp
* Mid Stage Products (Phase II)
* Early Stage Products (Phase I/II)
* TSHA-102: Taysha GTx
* Preclinical and Discovery Stage Products
* Inactive Products
* Rett Syndrome Key Companies
* Rett Syndrome Key Products
* Rett Syndrome- Unmet Needs
* Rett Syndrome- Market Drivers and Barriers
* Rett Syndrome- Future Perspectives and Conclusion
* Rett Syndrome Analyst Views
* Rett Syndrome Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=rett-syndrome-clinical-trial-pipeline-accelerates-as-20-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/rett-syndrome-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rett Syndrome Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight here
News-ID: 4315972 • Views: …
More Releases from ABNewswire
5 Gang Control Boat Rocker switch Panel
The Marine alis a project that creates a control panel with five separate es or buttons. These types of controls allow ship operators, RV operators and camper operators to centralize their control of the following types of equipment: All equipment requiring control from these types of control panels falls into the category of mobile (in-motion) vehicles. Electric [https://www.welfnobl.com/electric/] Control Panel for Gang Ship Type 5 [https://www.welfnobl.com/ib-p809-5-gang-control-boat-rocker-switch-panel-product/] Rocker Switch [https://www.welfnobl.com/rocker-switch/] Power,…
Exosomes Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge i …
DelveInsight's "Exosomes Pipeline Insight 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Exosomes Pipeline?…
3D Laser Printer Software for SLA and SLM: Transforming Precision Manufacturing
As digital manufacturing accelerates worldwide, advanced 3d printing software has become the backbone of high-precision production. Whether used for polymer-based stereolithography (SLA) or metal-focused selective laser melting (SLM), the best 3d printing software [https://www.ezcad.com/products/3d-laser-printing-software/] determines printing accuracy, surface quality, and overall workflow efficiency. Modern sla 3d software now integrates AI-driven slicing, intelligent support structures, and high-speed laser path optimization, allowing manufacturers to achieve new levels of performance in the 3D…
Top 10 Hex Bolts Used in Industrial Engineering
David Dai [https://www.cnzyl.com/]
sales
Ningbo Zhongli Bolts Manufacturing Co., Ltd. founded in 2003, is a professional manufacturer of high-strength fasteners in different specifications for various models, which is covering an area of about 10,000 square meters, registered capital of 1500,000 RMB, with the total annual productivity of 8,000 tons per year. The company has set up several sales branches in different provinces in China. Meanwhile, the company's products are exported to Europe,…
More Releases for Rett
Rett Syndrome Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction
Rett syndrome is a rare, progressive neurodevelopmental disorder that almost exclusively affects girls, with an incidence of roughly 1 in 10,000 to 15,000 live female births. The condition is caused primarily by mutations in the MECP2 gene, which plays a vital role in regulating brain development and synaptic function. Children with Rett syndrome typically develop normally for the first 6 to 18 months of life before symptoms such as motor…
Rett Syndrome Market: Increasing Awareness and Early Diagnosis and Advances in G …
06-06-2024: Maximize Market Research is a Business Consultancy Firm that has published a detailed analysis of the " Rett Syndrome Market". The report includes key business insights, demand analysis, pricing analysis, and competitive landscape. The analysis in the report provides an in-depth aspect at the current status of the Rett Syndrome Market, with forecasts outspreading to the year 2030.
Rett Syndrome Market size was valued at USD 350.1…
Rett Syndrome Market Industry Outlook, Size, Growth Factors and Forecast 2030
Rett Syndrome Market Insights Unveiled:
Embark on a riveting journey through the realms of the Rett Syndrome Market with the cutting-edge market intelligence of a distinguished global research firm. Immerse yourself in a rich tapestry of data and captivating visual representations that decode the enigmatic trends of both regional and global markets. This comprehensive report reveals the market's deepest ambitions, shedding luminous beams on the foremost competitors, their market valuation,…
"Understanding Rett Syndrome: Trends and Advances in the Rett Syndrome Market"
The Rett Syndrome Market, valued at USD 225.02 million in 2022, is anticipated to surge to USD 515.06 million by 2029, reflecting a significant Compound Annual Growth Rate (CAGR) of 10.23% from 2023 to 2029.
Overview of the Rett Syndrome Market:
Rett syndrome, a rare genetic neurological and developmental disorder primarily impacting females, hinders brain development and causes progressive loss of motor skills and language. The market report underscores technological advancements…
Europe Rett Syndrome Market Size, Share, Industry, Forecast to 2029
The Europe Rett Syndrome Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Europe Rett Syndrome market. This report explores all the key factors affecting the growth of the global Europe Rett…
Rett Syndrome: A Rare Disease Market with Huge Untapped Potential
What is Rett Syndrome?
Rett Syndrome is a rare genetic neurological disorder that primarily affects girls. It is caused by a mutation in the MECP2 gene, which is located on the X chromosome. The MECP2 gene provides instructions for making a protein that is critical for the normal development of the brain.
Rett Syndrome is a rare disorder, affecting about 1 in every 10,000 to 15,000 live female births. It is a…
